MindWalk (HYFT) & Its Rivals Head-To-Head Review

MindWalk (NASDAQ:HYFT) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it contrast to its rivals? We will compare MindWalk to related businesses based on the strength of its analyst recommendations, institutional ownership, valuation, risk, dividends, profitability and earnings.

Valuation and Earnings

This table compares MindWalk and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MindWalk	$11.24 million	-$10.11 million	-4.00
MindWalk Competitors	$2.28 billion	$55.88 billion	-14.01

MindWalk’s rivals have higher revenue and earnings than MindWalk. MindWalk is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

MindWalk has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, MindWalk’s rivals have a beta of 0.94, suggesting that their average stock price is 6% less volatile than the S&P 500.

Insider and Institutional Ownership

6.7% of MindWalk shares are held by institutional investors. Comparatively, 53.7% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 6.8% of MindWalk shares are held by company insiders. Comparatively, 15.0% of shares of all “Life Sciences Tools & Services” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares MindWalk and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MindWalk	-105.11%	-133.26%	-77.78%
MindWalk Competitors	-540.60%	-166.50%	-13.58%

Analyst Recommendations

This is a summary of recent ratings for MindWalk and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1	1	2	1	2.60
MindWalk Competitors	948	3168	5486	178	2.50

MindWalk currently has a consensus price target of $5.00, suggesting a potential upside of 380.77%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 3.81%. Given MindWalk’s stronger consensus rating and higher possible upside, equities research analysts plainly believe MindWalk is more favorable than its rivals.

Summary

MindWalk rivals beat MindWalk on 7 of the 12 factors compared.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.